EUROPEAN COMMUNITY

COMMENTS ON

CODEX CIRCULAR LETTER CL 2003/11 – RVDF

Report of the 14th session of the Codex Committee on Residues of Veterinary Drugs in Foods (Alinorm 03/31A) - Request for comments

Part A (appendix II, III and V):

The European Community would like to make the following comments regarding acceptance of MRLs proposed at step 8 (appendix II), 5/8 (appendix III) and step 5 (appendix V), respectively:

In accordance with the scientific assessment performed, the MRLs proposed for the following substances can be accepted from the point of view of adequate protection of human health: clenbuterol (with the footnote regarding the restriction in use), deltamethrin and dihydrostreptomycin/streptomycin. Nevertheless, the maximum residue limits legally permitted in the European Union may differ to those proposed as Codex standards.

The draft MRLs proposed for cefuroxime proposed at step 5 can be accepted, under the condition that the concerns expressed by the European Community in its previous comments are fully considered by JECFA. It should be underlined that the agreement to advance substance to step 5 does not mean that the European Community will agree to further advancement. Any such agreement would depend on the outcome of further evaluation and discussion by JECFA and CCRVDF on this substance. The European Agency for Evaluation of Medicinal Products will submit the detailed scientific considerations on the evaluation of cefuroxime to the JECFA secretariat.

Part B (ii): Draft Code of Practice to minimize and contain antimicrobial resistance

The European Community has previously submitted comments on the draft Code of Practice to minimize and contain antimicrobial resistance and supports the decision of the 14th CCRVDF to further develop definitions of antimicrobial, therapeutic and non-therapeutic as well as a general glossary.